Form D · Biotechnology

Prelude Corp

Laguna Hills, CA · CIK 0001669317

Offering snapshot reported Nov 6, 2025 · SEC filing

Reported sold
$5M
Offering amount: $7.5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 30, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 6, 2025Initial$5,000,000No comparison1SEC filing
Feb 15, 2022Initial$9,281,159No comparison32SEC filing
Jan 10, 2020Initial$10,000,013No comparison7SEC filing
Jul 27, 2018Initial$8,999,991No comparison7SEC filing
Mar 15, 2017Initial$5,499,998No comparison7SEC filing
Mar 15, 2016Initial$2,150,002No comparison4SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-563341

Source: Form D, filed Nov 6, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Gerrit Adams Director
Olav B. Bergheim Director, Executive
Daniel Forche Director, Executive
William J. Link Director
Derek Maetzold Director
Hugh Neuharth Director
Alejandro Sanchez Director
Andrew Wade Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
26051 Merit Circle Suite 102
Laguna Hills, CA, 92653